Cell and gene therapy development differs sharply from traditional drug development. Treatments consist of live cells, DNA or RNA sequences, or genetically modified immune cells; development is complicated and often personalized; and manufacturing requires special GMP facilities, cell processing, and viral vector production that are complicated to scale. These features explain why sponsors turn...